Sixty Degree Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)Ivan Cheung(Chief Executive Officer)Leena Gandhi(Chief Medical Officer)Tatiana Novobrantseva(Chief Scientific Officer)Axel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactSanofi VenturesCatalio Capital ManagementInvusLeaps by Bayer
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.